Federated Hermes Inc. Buys New Shares in Hologic, Inc. (NASDAQ:HOLX)

Federated Hermes Inc. acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,313 shares of the medical equipment provider’s stock, valued at approximately $246,000.

Other institutional investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its position in shares of Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after acquiring an additional 2,753,016 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Hologic by 4.0% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after buying an additional 87,176 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Hologic by 117.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after purchasing an additional 1,168,564 shares during the last quarter. TD Asset Management Inc grew its holdings in shares of Hologic by 2.0% during the 1st quarter. TD Asset Management Inc now owns 1,934,841 shares of the medical equipment provider’s stock valued at $150,840,000 after purchasing an additional 37,136 shares during the last quarter. Finally, Earnest Partners LLC grew its holdings in Hologic by 5.8% in the 1st quarter. Earnest Partners LLC now owns 1,814,028 shares of the medical equipment provider’s stock worth $141,422,000 after acquiring an additional 99,084 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on HOLX shares. Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 18th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $82.00 target price on shares of Hologic in a report on Friday, August 16th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, September 17th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.60.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock worth $1,469,973 over the last three months. Insiders own 1.75% of the company’s stock.

Hologic Price Performance

Hologic stock opened at $81.21 on Wednesday. The company has a fifty day simple moving average of $80.96 and a 200-day simple moving average of $77.20. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $18.95 billion, a price-to-earnings ratio of 41.43, a PEG ratio of 2.53 and a beta of 0.98. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. Hologic’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.93 earnings per share. On average, equities analysts anticipate that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.